A61P 13 - Drugs for disorders of the urinary system

Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
10/2002
10/17/2002	WO2001041760A8 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
10/17/2002	US20020152481 Genetic engineering; qualitative analysis
10/17/2002	US20020151588 Dissociated glucocorticoid receptor antagonists for the treatment of glucocorticoid associated side effects
10/17/2002	US20020151573 Anticancer agents
10/17/2002	US20020151554 Cyclin-dependent kinase inhibitors such as (4-Amino-2-((4-(4-methyl-1-piperazinyl)phenyl)amino)-5-thiazolyl) (2,3-dihydro-1,4-benzodioxin-6-yl)methanone for treatment of breast, lung, colon, and prostate cancer/tumors
10/17/2002	US20020151498 Medicaments that modify activity of Lipolysis Stimulated Receptor and that can be used to influence partitioning of dietary lipids between liver and peripheral tissues, including adipose tissue
10/17/2002	US20020151472 Trefoil factor (TFF) peptides (tricyclic peptides, e.g., TFF2 peptides), for increasing the viscosity of mucus layers; used for treating damaged or abnormal mucus layers, e.g. in the gastrointestinal tract, respiratory/urogential systems, eyes
10/17/2002	US20020151015 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
10/17/2002	US20020150984 Peptides for activation and inhibition of deltaPKC
10/17/2002	US20020150980 Nucleotide sequences coding protein for use in the treatment of asthma, parkinson's, heart, hypotension, osteporosis and urogenital disorders
10/17/2002	US20020150638 Solid form compositions containing an extract of a raw material as the active ingredient and process of preparing the same
10/17/2002	US20020150624 Mixture of drug, aminoacrylate polymer and acid
10/17/2002	US20020150587 Immunological polypeptides; vaccine against gramnegative bacteria
10/17/2002	DE10118550A1 New 3-ethanoylamino-3-phenyl-propionic acid derivatives, are integrin agonists or antagonists useful e.g. for treating angiogenic, cardiovascular, inflammatory, osteolytic or tumor diseases or infections
10/17/2002	CA2699611A1 Desaturase genes and uses thereof
10/17/2002	CA2698579A1 Desaturase genes and uses thereof
10/17/2002	CA2443405A1 Use of cd25 binding molecules in steroid-resistant patients
10/17/2002	CA2443042A1 Novel use of arylethene sulfonamide derivatives
10/17/2002	CA2443031A1 Use of selective cox-2 inhibitors for the treatment of urinary incontinence
10/17/2002	CA2443025A1 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
10/17/2002	CA2442991A1 Compositions and methods for the prevention and treatment of human prostate cancer
10/17/2002	CA2442776A1 Antagonists of mcp-1 function and methods of use thereof
10/17/2002	CA2442739A1 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
10/17/2002	CA2442382A1 Methods for using annexin for detecting cell death in vivo and treating associated conditions
10/17/2002	CA2441542A1 Method for preventing acute renal failure
10/17/2002	CA2441442A1 Conjugate of hydroxyalkyl starch and an active agent
10/17/2002	CA2440724A1 Pyrazolopyrimidines as therapeutic agents
10/16/2002	WO2001079186A1 2-guanidino-4-arylchinazolines as nhe-3 inhibitors
10/16/2002	EP1249241A1 Adsorbent for oral administration
10/16/2002	EP1248849A1 Obg3 globular head and uses thereof for decreasing body mass
10/16/2002	EP1248843A2 Nphs2 gene involved in the cortico-resistant neprhotic syndrome, protein encoded by said gene and diagnostic and therapeutic uses
10/16/2002	EP1248842A1 2871 receptor, a g-protein coupled receptor and methods of use thereof
10/16/2002	EP1248837A2 Angiotensin converting enzyme homolog and its use
10/16/2002	EP1248804A2 Recombinant antibodies to human interleukin-1 beta
10/16/2002	EP1248801A1 Human polynucleotides, polypeptides, and antibodies
10/16/2002	EP1248785A1 Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same
10/16/2002	EP1248784A1 Condensed azepines as vasopressin agonists
10/16/2002	EP1248782A1 Anticancer compound and enantiomer separation method useful for synthesizing said compound
10/16/2002	EP1248781A1 Pyrazole cyclic amp-specific pde inhibitors
10/16/2002	EP1248624A1 3,4-DIHYDRO-(1H)-QUINAZOLIN-2-ONES AND THEIR USE AS CSBP/p38 KINASE INHIBITORS
10/16/2002	EP1248615A1 Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging
10/16/2002	EP1248612A1 Novel compounds and compositions as protease inhibitors
10/16/2002	EP1248610A2 Use of at least a fatty ester for preparing a composition designed to inhibit 5-alpha-reductase activity, in pharmacology, in particular dermatology, in cosmetics and as food additive
10/16/2002	EP1248530A1 Canine health diet
10/16/2002	EP1140065A4 Use of gamma-tocopherol and its oxidative metabolite llu-alpha in the treatment of disease
10/16/2002	EP0941108B1 Wound healing and treatment of fibrosis
10/16/2002	EP0641203B1 Pharmaceutical compositions of an imidazolyl-akenoic acid salt and their use as angiotensin ii antagonists
10/16/2002	CN1374967A Compounds for the treatment of ischemia
10/16/2002	CN1374963A Remedies or preventives for freqent urination or arinary incontinence
10/16/2002	CN1374962A 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i] purin-5-one derivatives
10/16/2002	CN1374961A Azepinoindole derivatives, the production and use thereof
10/16/2002	CN1374960A Novel integrain receptor antagonists
10/16/2002	CN1374952A Benzimidazolone derivatives and their use as phosphodiesterase inhibibors
10/16/2002	CN1374857A Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins
10/16/2002	CN1374107A Chinese medicine for treating prostatitis, prostate hyperplasia and prostatauxe
10/16/2002	CN1374101A Kidney benefiting belt
10/16/2002	CN1374096A Prostatauxe treating medicine
10/16/2002	CN1092652C 2-imidazolinylaminoindole compound and composition containing the same use
10/16/2002	CN1092642C Quinoline derivatives as tachykinin NK 3 receptor antagonists
10/16/2002	CA2406161A1 2-guanidino-4-arylquinazolines as nhe-3 inhibitors
10/15/2002	US6465715 Dna fragments from the promoter region of the c. elegans ul6 gene which are capable of functioning as promoters directing gene expression in the excretory cell of c. elegans are provided and also expression vectors and transgenic c. elegans
10/15/2002	US6465513 Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
10/15/2002	US6465507 Antitumor agents
10/15/2002	US6465493 Such as 4-(4-(4-fluorophenyl)-5-(2-pyridyl)-1-hydroxy-1h-imidazol-2-yl)benzonitrile; alk5 mediated diseases such as arthritis, osteoporosis, kidney and renal diseases, conges-tive heart failure, ulcers, diabetic nephropathy
10/15/2002	US6465458 Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor
10/15/2002	US6464998 Composition for the in vivo production of therapeutic products
10/15/2002	CA2253795C Substituted 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors
10/15/2002	CA2191837C Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof
10/15/2002	CA2066943C Heterocyclically substituted phenylacetic acid derivatives, processes for their preparation and their use in medicaments
10/15/2002	CA2038985C Haloethyl-substituted steroidal enzyme inhibitors
10/11/2002	CA2357110A1 Method for the treatment of polycystic kidney disease
10/10/2002	WO2002079456A2 A method for the preparation of immunologically inert amniotic membranes
10/10/2002	WO2002079448A2 G-protein coupled receptors
10/10/2002	WO2002079441A2 Secreted proteins
10/10/2002	WO2002079408A2 Short bioactive peptides and methods for their use
10/10/2002	WO2002079256A1 Antibody and utilization thereof
10/10/2002	WO2002079195A1 Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines with adenosine receptor-binding activity and their use as cardiovascular preparations
10/10/2002	WO2002079188A1 Pyrrolidine sulfonamides
10/10/2002	WO2002079169A1 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
10/10/2002	WO2002079155A1 Pyrrolidine sulfonamides
10/10/2002	WO2002079152A1 Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
10/10/2002	WO2002079147A2 Inhibitors of prenyl-protein transferase
10/10/2002	WO2002079146A2 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
10/10/2002	WO2002078712A1 Remedies for vesical stimulation in association with prostatauxe
10/10/2002	WO2002078711A1 Remedies for vesical hyperesthesia
10/10/2002	WO2002078710A1 Remedies for vesical hyperactivity
10/10/2002	WO2002078705A1 Hsp inductor
10/10/2002	WO2002078683A1 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
10/10/2002	WO2002078682A2 Estrogen replacement therapy
10/10/2002	WO2002078680A1 Gaba-receptor modulators for the treatment of neurodegenerative diseases of the eye
10/10/2002	WO2002078633A2 Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia
10/10/2002	WO2002078523A2 Agent for the treatment of overactive bladder
10/10/2002	WO2002046373A8 Method of collecting placental stem cells
10/10/2002	WO2002004612A3 Drug metabolizing enzymes
10/10/2002	WO2001098353A3 Secreted proteins
10/10/2002	WO2001093845A3 Carboxyalkylether-acat inhibitor combinations
10/10/2002	WO2001077174A3 Human transporters and ion channels
10/10/2002	WO2001072728A9 Novel piperazine derivatives
10/10/2002	US20020147343 Cell antiproliferative agents; anticancer agents
10/10/2002	US20020147341 Kinase inhibitor; benign prostatic hyperplasia

1 ... 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 ... 562